Investing Ideas
/
Polish Pharmaceuticals & Biotech Healthy potentially undervalued

Polish Pharmaceuticals & Biotech Healthy potentially undervalued

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

0 new

Companies which are potentially undervalued and in an acceptable financial position.

1 companies

Selvita

Market Cap: zł543.3m

Provides drug discovery, drug development, and contract testing services in Poland.

SLV

zł29.95

0.3%

-0.8%